PRESS RELEASE
Ad hoc announcement pursuant to article 53 LR

LEPU Medical Technology(Beijing) Announces Results for the Third Quarter of 2025

Beijing, China, October 25, 2025- LEPU Medical Technology(Beijing) Co.,Ltd.(the "Company") today announced its performance for the nine months ended September 30, 2025:

In the third quarter, the Company achieved operating income of 1569.3247 million yuan. Among which:Cardiovascular Implantation and Intervention: Operating income of 554.5504 million yuan, a year-on-year increase of 7.18%. Surgical Anesthesia: Operating income of 95.1105 million yuan, a year-on-year decrease of 37.38%;In Vitro Diagnostics: Operating income of 64.6971 million yuan, a year-on-year decrease of 17.45%.

Pharmaceutical Preparations Sales: Steady recovery, with operating income of 386.8486 million yuan, a year-on-year increase of 53.08%;

Medical Services and Health Management: Operating income of 320.9342 million yuan, a year-on-year increase of 28.27%. Among which, revenue from "Tongyanzhen" (Facial Rejuvenation Injections) and "Shuiguangzhen" (Hydrating Injections) reached 86.1367 million yuan.

In this quarter, the company achieved a net profit attributable to shareholders of listed companies of RMB 291.1271 million, representing a year-on-year increase of 176.18%; and a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of RMB 278.7114 million, with a year-on-year growth of 220.63%.

In the third quarter, the Company achieved net cash flow from operating activities of 376.3125 million yuan.

During the reporting period, the Company accumulated operating income of 4938.7092 million yuan, an increase of 153.2376 million yuan or 3.20% compared with the same period last year.

1) The medical device segment is the largest revenue-generating segment of the Company's business. During the reporting period, this segment achieved operating income of 2571.8806 million yuan, a year-on-year increase of 0.33%. Cardiovascular implantation and intervention business: achieved operating income of 1793.1484 million yuan, a year-on-year increase of 7.45%. Surgical anesthesia business: achieved operating income of 336.1155 million yuan, a year-on-year decrease of 20.08%. In vitro diagnostics business: achieved operating income of 228.0685 million yuan, a year-on-year decrease of 17.38%.

2) Pharmaceuticals achieved operating income of 1570.4223 million yuan, a year-on-year increase of 6.37%, of which: active pharmaceutical ingredients (APIs) achieved operating income of 208.2283 million yuan, a decrease of 26.89% compared with the same period last year; preparations achieved operating income of 1362.1940 million yuan, an increase of 14.32% compared with the same period last year.

3) Medical services and health management achieved operating income of 796.4063 million yuan, a year-on-year increase of 6.79%. Among them, Hefei Cardiovascular Hospital achieved operating income of 125.9417 million yuan, an increase of 5.16% compared with the same period last year; Lepu Yunzhi Technology achieved operating income of 420.3637 million yuan, a year-on-year increase of 7.27%.

During the reporting period, the Company achieved a net profit of 995.9943 million yuan; net profit attributable to shareholders of the listed company was 982.0530 million yuan, a year-on-year increase of 22.35%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 940.9072 million yuan, a year-on-year increase of 28.18%; net cash flow from operating activities was 1012.6770 million yuan, a year-on-year increase of 139.37%.

Financial Results (unaudited)

	Three Months Ended September 30, 2025	% Change	Nine Months Ended September 30, 2025	% Change
Operating revenue(RMB)	1,569,324,667.97	11.97%	4,938,709,224.18	3.20%
Net profit attributable to shareholders of the Company (RMB)	291,127,122.27	176.18%	982,053,022.16	22.35%
Net profit attributable to shareholders of the Company after deducting non-recurring profit and loss (RMB)	278,711,419.15	220.63%	940,907,198.82	28.18%
Net cash flows from operating activities (RMB)	--	--	1,012,677,029.32	139.37%
Basic earnings per share (RMB /share)	0.1579	177.02%	0.5327	22.77%
Diluted earnings per share (RMB /share)	0.1579	177.02%	0.5327	22.77%
Return on weighted average net assets	1.81%	1.15%	6.25%	Increase 1.24%

Full third quarter report

The full three-quarter results report as of and for the nine months ended September 30, 2025 is available on our website at https://en.lepumedical.com/investors/.

Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

Disclaimers

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects,""intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current

views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.